论文部分内容阅读
目的:比较甘精胰岛素与诺和灵30R治疗新诊断2型糖尿病(T2DM)的疗效。方法:将80例T2DM患者随机分为2组,分别应用甘精胰岛素(A组)和诺和灵30R(B组)进行24周的强化治疗,比较2组一般情况及血糖控制情况。结果:治疗后2组血糖、血压均达到目标水平,降低程度无显著差异。B组较A组低血糖发生率更高,体重增加幅度更大。结论:甘精胰岛素与诺和灵30R对新诊断T2DM的降糖效果无显著差异,但后者的低血糖风险大,体重增加幅度大。说明甘精胰岛素更适合于新诊断T2DM患者。大量研究表明,胰岛素强化治疗可以有效降低新诊断T2DM患者的空腹、餐后血糖,使糖化血红蛋白(HbAlc),并减少大、小血管的并发症,但可增加低血糖的发生率和体重增加。本研究将比较甘精胰岛素与诺和灵30R对新诊断2型糖尿病(T2DM)的疗效,为更好地治疗新诊断2型糖尿病提供临床依据。
Objective: To compare the efficacy of insulin glargine and Novolin 30R in newly diagnosed type 2 diabetes mellitus (T2DM). Methods: Eighty T2DM patients were randomly divided into two groups. The patients were treated with glargine (A group) and Novolin 30R (B group) for 24 weeks. The general conditions and the control of blood glucose were compared between the two groups. Results: After treatment, blood sugar and blood pressure reached the target level in both groups, with no significant difference in the degree of reduction. The incidence of hypoglycemia in group B was higher than that in group A, and the weight gain was even greater. CONCLUSION: There is no significant difference in the hypoglycemic effect of insulin glargine and norepinephrine 30R on newly diagnosed T2DM, but the risk of hypoglycemia in the latter is high and the rate of weight gain is large. Glargard is more suitable for newly diagnosed T2DM patients. A large number of studies have shown that intensive insulin therapy can effectively reduce the fasting and postprandial blood glucose in patients with newly diagnosed T2DM, reduce the complications of large and small blood vessels, and increase the incidence of hypoglycemia and weight gain. This study will compare the efficacy of insulin glargine and Novolin 30R in newly diagnosed type 2 diabetes mellitus (T2DM) and provide a clinical basis for better treatment of newly diagnosed type 2 diabetes.